Equities analysts expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) to announce $5.63 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Teva Pharmaceutical Industries Limited’s earnings, with the lowest sales estimate coming in at $5.58 billion and the highest estimate coming in at $5.72 billion. Teva Pharmaceutical Industries Limited posted sales of $5.56 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 1.3%. The business is expected to issue its next earnings report on Tuesday, November 21st.

On average, analysts expect that Teva Pharmaceutical Industries Limited will report full year sales of $5.63 billion for the current financial year, with estimates ranging from $22.40 billion to $23.01 billion. For the next fiscal year, analysts forecast that the company will post sales of $22.10 billion per share, with estimates ranging from $21.39 billion to $22.90 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the prior year, the business earned $1.25 earnings per share. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis.

TEVA has been the topic of several recent research reports. Citigroup Inc. reduced their price target on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, April 25th. Vetr cut Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $35.15 price target on the stock. in a research note on Monday, April 24th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 17th. Deutsche Bank AG reduced their price target on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, May 12th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 31st. Three investment analysts have rated the stock with a sell rating, nineteen have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited has a consensus rating of “Hold” and a consensus target price of $37.69.

Teva Pharmaceutical Industries Limited (TEVA) opened at 17.97 on Wednesday. Teva Pharmaceutical Industries Limited has a one year low of $16.81 and a one year high of $53.96. The company has a 50 day moving average price of $28.78 and a 200-day moving average price of $31.30. The company’s market capitalization is $18.26 billion.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 1.89%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is -18.95%.

A number of hedge funds and other institutional investors have recently bought and sold shares of TEVA. Greylin Investment Mangement Inc. increased its position in Teva Pharmaceutical Industries Limited by 36.9% in the second quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock worth $9,783,000 after buying an additional 79,300 shares in the last quarter. PGGM Investments increased its position in Teva Pharmaceutical Industries Limited by 12.0% in the second quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock worth $50,763,000 after buying an additional 163,292 shares in the last quarter. Schulhoff & Co. Inc. increased its position in Teva Pharmaceutical Industries Limited by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock worth $372,000 after buying an additional 1,004 shares in the last quarter. Bank Hapoalim BM increased its position in Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock worth $375,000 after buying an additional 980 shares in the last quarter. Finally, Coastline Trust Co increased its position in Teva Pharmaceutical Industries Limited by 3.6% in the first quarter. Coastline Trust Co now owns 29,990 shares of the company’s stock worth $962,000 after buying an additional 1,040 shares in the last quarter. 56.04% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/16/teva-pharmaceutical-industries-limited-teva-expected-to-announce-quarterly-sales-of-5-63-billion.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries Limited (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.